Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Conivaptan hydrochloride

Base Information Edit
  • Chemical Name:Conivaptan hydrochloride
  • CAS No.:168626-94-6
  • Molecular Formula:C32H26N4O2*ClH
  • Molecular Weight:535.045
  • Hs Code.:
  • UNII:75L57R6X36
  • DSSTox Substance ID:DTXSID70168585
  • Wikidata:Q27114306
  • NCI Thesaurus Code:C65351
  • RXCUI:1294548
  • ChEMBL ID:CHEMBL1201108
  • Mol file:168626-94-6.mol
Conivaptan hydrochloride

Synonyms:(1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-;(1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-, monohydrochloride;4''-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide;CI-1025;conivaptan;conivaptan HCl;conivaptan hydrochloride;Vaprisol;YM 087;YM-087;YM087

Suppliers and Price of Conivaptan hydrochloride
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • TRC
  • ConivaptanHydrochloride
  • 25mg
  • $ 85.00
  • Tocris
  • Conivaptanhydrochloride ≥98%(HPLC)
  • 10
  • $ 50.00
  • Tocris
  • Conivaptanhydrochloride ≥98%(HPLC)
  • 50
  • $ 214.00
  • Matrix Scientific
  • Conivaptan hydrochloride 95+%
  • 1g
  • $ 1143.00
  • Matrix Scientific
  • Conivaptan hydrochloride 95+%
  • 250mg
  • $ 515.00
  • DC Chemicals
  • Conivaptanhydrochloride >99%
  • 1 g
  • $ 800.00
  • CSNpharm
  • ConivaptanHCl
  • 100mg
  • $ 320.00
  • Crysdot
  • Conivaptanhydrochloride 98+%
  • 100mg
  • $ 431.00
  • Crysdot
  • Conivaptanhydrochloride 98+%
  • 50mg
  • $ 247.00
  • ChemScene
  • Conivaptanhydrochloride 99.92%
  • 10mg
  • $ 96.00
Total 124 raw suppliers
Chemical Property of Conivaptan hydrochloride Edit
Chemical Property:
  • Vapor Pressure:1.89E-22mmHg at 25°C 
  • Melting Point:>250° 
  • Boiling Point:751.2 °C at 760 mmHg 
  • Flash Point:408.1 °C 
  • PSA:78.09000 
  • LogP:7.44730 
  • Storage Temp.:under inert gas (nitrogen or Argon) at 2-8°C 
  • Solubility.:DMSO (Slightly), Methanol (Slightly) 
  • Hydrogen Bond Donor Count:3
  • Hydrogen Bond Acceptor Count:3
  • Rotatable Bond Count:4
  • Exact Mass:534.1822538
  • Heavy Atom Count:39
  • Complexity:820
Purity/Quality:

99% *data from raw suppliers

ConivaptanHydrochloride *data from reagent suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:

SDS file from LookChem

Useful:
  • Canonical SMILES:CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6.Cl
  • Recent ClinicalTrials:A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol?) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
  • Recent EU Clinical Trials:Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure
  • Description Arginine vasopressin is intimately involved in volume homeostasis, and elevated levels of arginine vasopressin are responsible for the pathogenesis and progression of diseases with an imbalance of sodium and water, particularly congestive heart failure. To restore homeostasis, antagonism of vasopressin receptors is a practical solution. As such, conivaptan has been developed and launched as a dual V1a and V2 vasopressin receptor antagonist. As a competitive, reversible inhibitor of both subtypes, conivaptan can modulate systemic vascular resistance through the V1a receptor (Ki ? 0.48 nM) distributed in vascular smooth muscle cells, cardiomyocytes, hepatocytes, and platelets and blocks the renal V2 receptor (Ki ? 3.04 nM) resulting in enhanced diuresis, thereby increasing serum sodium concentration and reducing total body volume. Currently, the drug is approved for the management of refractory hyponatremia and potentially lifethreatening sodium and water imbalance, but it has shown promise as a potential treatment option for other diseases, such as congestive heart failure, syndrome of antidiuretic hormone, diabetes insipidus, and liver cirrhosis. Conivaptan is an antagonist of the arginine vasopressin (AVP) receptors V1A and V2 (Kis = 0.48 and 3.04 nM for rat liver V1A and kidney V2, respectively). It also competitively inhibits oxytocin binding to rat uterine oxytocin receptors (Ki = 44 nM) but has no effect on AVP binding to anterior pituitary V1B receptors at concentrations up to 100 μM in a radioligand binding assay. Conivaptan suppresses AVP-induced increases in intracellular calcium in vascular smooth muscle cells (VSMCs) in vitro and the pressor response in pithed rats. Conivaptan (0.01-0.3 mg/kg, i.v.) increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner. It also reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model.
  • Uses Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). Used in treatment of congestive heart failure.
Technology Process of Conivaptan hydrochloride

There total 15 articles about Conivaptan hydrochloride which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:
Guidance literature:
o-phenylbenzoyl chloride; {4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}amine; With pyridine; In acetonitrile; at 0 - 25 ℃; Reflux;
With hydrogenchloride; In ethyl acetate; acetonitrile; at 5 - 30 ℃; for 0.5h;
DOI:10.1021/op034079e
Guidance literature:
With water; potassium carbonate; In chloroform; for 20h; Reflux; Green chemistry;
Guidance literature:
With hydrogenchloride; In ethanol; ethyl acetate;
DOI:10.1021/op034079e
Post RFQ for Price